| 规格: | 98% |
| 分子量: | 637.7 |
| 包装 | 价格(元) |
| 1mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
Background:
Risuteganib is an anti-integrin peptide and a derivative of RGD peptide .1Risuteganib (400 µM) protects against hydroquinone-induced necrosis and apoptosis, as well as inhibits hydroquinone-induced production of reactive oxygen species (ROS), in human retinal pigment epithelial (RPE) cells.2It decreases the expression ofBAX,VEGFA, andITB1in human age-related macular degeneration (AMD) cybrid cell lines when used at a concentration of 20 mg/ml.3Risuteganib arrests aberrant blood vessel growth mediated by αVβ3, αVβ5, and α5β1 integrinsin vivo.1
1.Kaiser, P., Boyer, D.D., Campochiaro, P.A., et al.Integrin peptide therapy: The first wet AMD experienceInvest. Opth. Vis. Sci.54(15)2177(2013) 2.Yang, P., Shao, Z., Besley, N.A., et al.Risuteganib protects against hydroquinone-induced injury in human RPE cellsInvest. Ophthalmol. Vis. Sci.61(10)35(2020) 3.Differential effects of risuteganib and bevacizumab on AMD cybrid cellsExp. Eye Res.203108287(2021)
m.cnreagent.com